What is Immunovia?
Immunovia AB is a Swedish diagnostic company specializing in the development and commercialization of highly accurate blood tests for the early detection of various cancers. Leveraging its proprietary IMMray test platform, which utilizes antibody biomarker microarray analysis combined with advanced machine-learning and bioinformatics, Immunovia aims to identify unique "disease biomarker signatures." Founded in 2007, the company's research is rooted in groundbreaking studies from Lund University and CREATE Health Cancer Center. Its initial product, IMMray PanCan-d, is designed for the early detection of pancreatic cancer and has been part of extensive clinical evaluations. The company expanded its operations to the USA in 2017, offering the IMMray PanCan-d test as a laboratory developed test (LDT).
How much funding has Immunovia raised?
Immunovia has raised a total of $43M across 1 funding round:
Share Placement
$43M
Share Placement (2020): $43M, investors not publicly disclosed
What's next for Immunovia?
The recent major strategic investment signals a pivotal phase for Immunovia, likely enabling the company to accelerate the clinical validation and commercialization of its IMMray PanCan-d test and potentially other cancer diagnostics. This capital is expected to fuel further research and development, expand its market reach, and solidify its position as a leader in early cancer detection through innovative blood-based biomarkers. The company's focus on high-risk groups for pancreatic cancer, coupled with its advanced technological platform, positions it for significant growth in the oncology diagnostics sector.
See full Immunovia company page
